I write to share a brief correspondence our team in Rwanda published in Nature this week about the possibility of achieving excellent MDR-TB treatment outcomes in rural Africa with the provision of close follow-up and comprehensive adherence support (especially food and transportation assistance).
Most discussion of MDR-TB in medical journals and the press has focused on the important need for new drugs and a vaccine, but not much attention has focused on the possibilities of using currently available tools in smart systems to reduce morbidity and mortality in the interim.
What are your experiences with MDR-TB treatment adherence, and the most important barriers to or facilitators of retention in care?
Dr. Agnes Binagwaho
Minister of Health of Rwanda
Senior Lecturer, Harvard Medical School
Clinical Professor of Pediatrics, Geisel School of Medicine at Dartmouth